125561

Under number 125561 , written evidence was submitted by Mrs. C. Roche to the UK Parliament regarding the impact of screen time and "digital drugs" on children’s brains and ADHD .

The identifier appears across several distinct contexts, most notably as an FDA application number for the drug Kanuma and as an article identifier for a research paper on optimal nonparametric inference using deep neural networks. Pharmaceutical: FDA BLA 125561 125561

It is an enzyme replacement therapy used to treat Lysosomal Acid Lipase (LAL) deficiency , a rare genetic condition. Under number 125561 , written evidence was submitted by Mrs